**Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020**

|  |
| --- |
| DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous 07.05.2020 / 07:00 The issuer is solely responsible for the content of this announcement.**Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Updateon May 14, 2020****HALLE (SAALE) / Munich, Germany, 7 May 2020** - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), which develops first-in-class drugs targeting post-translational modifying enzymes, will publish its first quarter business update for the period ended March 31, 2020 on Thursday, May 14, 2020, in the form of an interim management report.###**For more information, please contact:****Vivoryon Therapeutics AG**Dr. Ulrich Dauer, CEOEmail: contact@vivoryon.com**Trophic Communications**Gretchen Schweitzer / Joanne TudoricaTel: +49 172 861 8540 / +49 176 2103 7191Email: Trophic@vivoryon.com**Notes to Editors:About Vivoryon Therapeutics AG**With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.[www.vivoryon.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=41d29022a53944e2850469d63ade149d&application_id=1037495&site_id=news_data&application_name=news)***Forward Looking Statements****Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*07.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de |

|  |  |
| --- | --- |
| Language: | English |
| Company: | Vivoryon Therapeutics AG |
|  | Weinbergweg 22 |
|  | 06120 Halle/Saale |
|  | Germany |
| Phone: | +49 (0)345 555 9900 |
| Fax: | +49 (0)345 555 9901 |
| E-mail: | contact@vivoryon.com |
| Internet: | www.vivoryon.com |
| ISIN: | DE0007921835 |
| WKN: | 792183 |
| Listed: | Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam |
| EQS News ID: | 1037495 |

|  |
| --- |
|  |

|  |
| --- |
|   |
| End of News | DGAP News Service |